Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 943 across all filing types
Latest filing 2025-11-07 Regulatory Filings
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the audio recordings of an earnings call conducted on November 7, 2025, for the quarter and half year ended September 30, 2025. It provides a link to the audio recording but does not contain the transcript or detailed financial data itself. The document is short (1140 characters) and serves as an announcement of the earnings call recording availability rather than the call transcript or financial report. According to the rules, announcements about earnings calls or their recordings are best classified as Call Transcript (CT) if the full transcript is provided, but since this is only a notification with a link to the audio recording, it is more appropriate to classify it as Regulatory Filings (RNS) because it is a regulatory announcement without substantive financial data or transcript text.
2025-11-07 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation Q2FY26 & H1FY26' and is addressed to stock exchanges pursuant to SEBI regulations, indicating it is an official investor communication. It contains detailed financial highlights, management commentary, business overview, and operational metrics for the quarter and half-year ended September 30, 2025. The content includes revenue, EBITDA, PAT, EPS, balance sheet metrics, and segment revenue analysis, which are typical components of an investor presentation. The document is approximately 15,000 characters long, indicating it is a full presentation rather than a brief announcement or a certification. There is no indication that this is a full annual or interim report with comprehensive financial statements, nor is it a transcript, audit report, or other filing type. Therefore, the document best fits the category of an Investor Presentation (IP).
2025-11-07 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the financial results for the quarter and half year ended September 30, 2025. It includes a financial summary with key figures such as total income, EBITDA, and profit after tax. It also mentions an upcoming earnings call to discuss the results. The document is not the full financial report but a summary announcement of quarterly financial results. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. H1 2026
2025-11-07 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 86% confidence The document is a SEBI Regulation 33 filing containing the unaudited consolidated financial results for the quarter and half year ended September 30, 2025, prepared under Ind AS 34 and accompanied by the auditor’s limited review report. It includes detailed interim financial statements (income, expenses, etc.) rather than merely announcing that results are available. This matches the definition of an Interim/Quarterly Report (IR). H1 2025
2025-11-07 English
Shareholders meeting
Regulatory Filings
2025-11-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges announcing the schedule for an upcoming earnings call for the second quarter and half year ended September 30, 2025. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, which governs disclosure of material events. The document does not contain any financial data or results itself but only provides information about the timing and registration details for the earnings call. The document length is short (2481 characters) and it is clearly an announcement of the earnings call, not the earnings release or the transcript. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about an upcoming earnings call, rather than an Earnings Release (ER) or Call Transcript (CT).
2025-10-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.